Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis — Jonathan Y. M. Lai (2024) | RDL Network
Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis
Article 2024 en
Authors
JL
Jonathan Y. M. Lai
DR
David R. Riley
MA
Matthew Anson
Abstract
1 min read
There was no statistically significant risk of cardiovascular-related events in the short or medium term in patients with diabetes who received intravitreal anti-VEGF therapy, despite a small increase in the number of CVD events. Our study supports the real-world safety of intravitreal anti-VEGF therapy in patients with diabetes free of baseline CVD.
Hicham Skali, Julie Lin, Marc A. Pfeffer, Chaoyin Chen, Mark E. Cooper, John J.V. McMurray, Allen R. Nissenson, Giuseppe Remuzzi, Patrick S. Parfrey, Nairne Scott‐Douglas, Ajay Singh
Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz, Vivian P. Thompson, Yuliya Lokhnygina, John B. Buse, Juliana C.N. Chan, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Aldo Maggioni, Steven P. Marso, Peter Öhman, Neha J. Pagidipati, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F. Hernandez
Discussion(0)
No comments yet. Be the first to comment.